Biotech Investment Checklist
- Identify the business model, lead treatment and ownership rights.
- Read the clinical evidence and identify what remains unproven.
- Check the regulatory route in each intended market.
- Estimate reachable patients, competition and commercial costs.
- Calculate cash runway and likely financing needs.
- Assess management’s decisions and track record.
- Compare valuation scenarios with the current share price.
- Choose your exposure and set a position size.
- Check the broker, trading costs and order conditions.
- Record the thesis and monitor evidence, funding and valuation.
Work through the steps below before committing money to an individual biotech company. Each stage supplies information needed by the next: clinical evidence shapes the commercial forecast, the development schedule shapes funding needs, and both affect what the shares may be worth. Keep a short research record as you go, separating disclosed facts from your own assumptions. You do not need a confident answer to every question, but you do need to recognise which unanswered questions could change the outcome. If the evidence is too difficult to assess or the financing plan depends on optimistic assumptions, leaving the company on a watchlist is a valid result of the process.
Step 1 Understand the Business and Ownership
Begin by writing down how the company expects to make money. A biotech investment often begins with a compelling medical idea: a treatment for patients who have few options, a different way to attack a disease, or a technology that could produce several medicines. For shareholders, the value depends on how that idea becomes a business. Research must produce convincing evidence, development must remain funded, and an eventual product must reach patients on terms that leave something for its owners. These stages can take years. A company can make scientific progress while its shareholders lose money, particularly if development costs rise or repeated financing leaves existing investors owning a smaller proportion of the eventual business.
The first distinction is between companies already selling products and those still developing their first treatment. An established biotech can be assessed through product sales and operating expenses, although its future also depends on competition and research. A developer without an approved medicine requires a different approach because much of its value rests on outcomes that have not happened. Businesses supplying laboratory equipment or research services introduce another set of economics, including customer budgets and demand for equipment. Decide which business you are analysing before comparing valuations. Two companies described as biotechnology stocks may have almost nothing in common in terms of how they earn revenue. For background on assessing businesses and comparing ways to invest, Investing.co.uk provides broader investing guides that can help establish the financial context before examining a developer’s clinical evidence.
Identify What Shareholders Actually Own
A pipeline describes the programmes a company is developing, but counting them tells you little about the independence of their risks. Several treatments may depend on the same delivery technology or biological mechanism. A problem with that shared approach could affect every programme, leaving a broad-looking pipeline with one underlying vulnerability. Establish which asset accounts for most of the investment case and what remains if it fails. A company testing one drug in several diseases has several possible markets, yet those opportunities still depend partly on the same molecule. The useful question is how much of the business survives a setback, rather than how many coloured bars appear in a presentation.
Ownership then determines how much value a successful treatment could create for the company. A developer may owe royalties to a university, share profits with a partner or retain commercial rights only in certain countries. Read the licensing disclosures alongside the pipeline presentation. A partnership advertised as worth billions may include a modest upfront payment and much larger amounts contingent on approval or future sales. Those future amounts are not cash in the bank. Establish who funds the remaining studies, who controls development and whether either party can terminate the agreement. A respected partner brings resources and scrutiny, but it can still change priorities or decide that a programme no longer justifies further spending. Before moving on, record the lead asset, its development stage and the share of its economics the company retains.
Step 2 Assess the Clinical Evidence
Understand What Each Trial Can Establish
Find the latest trial results and the study’s stated objectives, then assess them together. Clinical trials answer defined questions about an experimental treatment. The FDA’s explanation of clinical research describes the usual progression: Phase 1 focuses heavily on safety and dosage, Phase 2 examines activity in patients and informs further development, and Phase 3 generally seeks stronger evidence of treatment benefit and safety. Designs vary by disease, and some programmes combine stages. Treat the phase number as context. An early study showing encouraging activity can justify another trial without establishing that the treatment will succeed in a larger population. For an investor, the distinction changes both the probability of eventual commercial success and the amount of money still needed to investigate it.
Consider a hypothetical company reporting improvement in eight of ten patients. That sounds encouraging, but the investment meaning depends on what improvement means and how those patients were selected. Was there a comparison group? How long did the benefit last, and did all ten patients complete the observation period? If the study enrolled an unusually responsive group, the result may not translate to the broader population. Small samples can also miss uncommon harms. The sensible next step is to assess whether the evidence supports further development and at what cost. Treating an early response rate as a reliable forecast of eventual sales skips most of the work that remains.
Separate the Main Result from Supporting Findings
The primary endpoint is the main outcome a study is designed to assess. It might measure survival, symptom improvement or another outcome relevant to the disease. Secondary endpoints provide further information, but they do not automatically rescue a study that misses its main objective. Read what the company said it intended to measure before results arrived, then compare that with what the announcement emphasises afterwards. A favourable analysis of a small subgroup may be useful for designing another trial, especially if there is a biological reason for the difference. Its reliability depends partly on whether the analysis was planned and how many other comparisons were examined.
A reported statistical result needs to be read alongside the size and practical meaning of the treatment effect. Suppose a treatment reduces an adverse event rate from 10% to 8%. That is a 20% relative reduction and a two percentage point absolute reduction; both describe the same result, but they create different impressions. Whether the change matters depends on the severity of the event, treatment burden and uncertainty around the estimate. Examine confidence intervals where reported and check the comparison treatment. A small benefit may still matter in a severe disease, while an inconvenient or risky treatment could require a larger benefit to justify its use.
Safety and Study Design Affect the Business Case
Safety influences more than the approval decision. Side effects can restrict which patients receive a medicine, require monitoring or encourage doctors to choose an alternative. Read discontinuations and serious adverse events alongside efficacy results, distinguishing events observed during treatment from those judged related to it. The comparison group helps provide context, especially in patients who are already seriously ill. Follow-up duration matters too. A treatment intended for years of use raises different questions from a short course, and an early benefit may weaken with time. Investors should ask what the available observation period can establish and what additional evidence would be needed to support the proposed commercial use.
Randomisation and blinding help reduce sources of bias, while a suitable comparator makes it easier to judge the treatment against available care. Eligibility rules also matter because trial participants may differ from patients treated in everyday practice. Check the registered study design on ClinicalTrials.gov and compare it with company disclosures and published results. The registry is a record of submitted information, not an endorsement of the product or a guarantee that every entry is current. Look for changes in recruitment targets, endpoints or expected completion dates and investigate the reason. A design change can be sensible, but it can also alter the time, cost and strength of evidence supporting the investment. Finish this step with a clear statement of what the evidence supports and which questions the next study must answer.
Step 3 Check the Regulatory Route
United States Approval and Earlier Access Pathways
Identify the intended launch markets and the approval work remaining in each. For a medicine intended for the United States, the FDA’s role should be distinguished from the company’s commercial objectives. Being allowed to begin a clinical study does not authorise sales of the treatment. Nor does an encouraging meeting with the regulator settle the eventual approval decision. A company may describe an expedited designation or review timetable as a milestone, but investors still need to establish what evidence remains outstanding. Under the FDA’s accelerated approval framework, some treatments can receive approval using certain endpoints that predict clinical benefit, with requirements to verify that benefit. That route changes the development timetable and obligations; it does not remove uncertainty about the product’s future.
Even a favourable clinical dataset leaves other matters to resolve. Manufacturing quality, the proposed patient population and the wording of the approved indication can affect whether and how a medicine reaches the market. A narrower label than investors expected may reduce eligible patients, while monitoring requirements can make treatment more cumbersome. Separate an expected application date from an expected decision date, and allow for requests for additional work. A delay can have financial consequences even if it does not invalidate the science: cash continues to be spent, competitors advance, and a company may need another financing before it can begin selling the product.
European and UK Decisions Are Separate
In the European Union, the European Medicines Agency evaluates medicines submitted through the centralised procedure, with the European Commission issuing the legally binding authorisation decision. The EMA’s explanation of medicine authorisation sets out that division of responsibility. The United Kingdom has its own medicines regulator, the MHRA. An approval in the United States therefore should not be counted as automatic access to either market. Reimbursement also involves further decisions and can differ between countries. When a valuation assumes global sales, identify the development, approval and market access work required for each territory. Otherwise, the model can attach worldwide revenue to evidence and commercial rights that support a much narrower opportunity. Record submission dates and decision dates separately, marking company estimates as estimates.
Step 4 Estimate the Commercial Opportunity
Translate Disease Numbers into Reachable Patients
Build the sales estimate from eligible patients upwards. A large disease population does not automatically create a large market for one medicine. Begin with the patients who would qualify under the likely indication, then consider how many are diagnosed and treated. A therapy intended for people who have failed earlier medicines addresses a different population from one used immediately after diagnosis. Testing requirements or the need to travel to a specialist centre can reduce access further. In a hypothetical disease affecting one million people, only a fraction may fit the proposed treatment criteria. Applying the proposed annual price to the full million would produce an impressive number, but a poor estimate of what the company could actually sell.
Adoption takes time, even when a medicine offers a useful benefit. Doctors need evidence that applies to their patients, treatment centres need capacity, and payers need to decide when they will cover the cost. A complicated administration process may slow uptake compared with an alternative patients can take at home. For a treatment intended to be given once, distinguish the existing pool of eligible patients from the smaller number newly diagnosed each year. Early demand from that existing pool may not support the same sales level indefinitely. Build an adoption curve that reflects how patients enter treatment and how quickly the healthcare system can serve them.
Examine Net Revenue and the Competitive Position
The published price is only a starting point for revenue estimates. Discounts, rebates and distribution arrangements can reduce the amount retained, and commercial rights may require the company to share the proceeds. Pricing and reimbursement arrangements differ between jurisdictions, so assumptions based on US sales should not be copied across a global forecast. Ask what the medicine offers relative to available treatment and whether that benefit supports the expected price. A product can achieve regulatory approval while struggling to gain favourable coverage. For shareholders, the relevant forecast combines the number of treated patients with realistic net revenue and the expense of supplying and selling the medicine.
Competition must be assessed at the likely launch date. A product several years from market may eventually compete against treatments that are still experimental today. Compare the strength and maturity of the evidence, dosing burden and likely place in treatment. Avoid declaring one drug superior solely because results from separate trials appear better: the studies may involve different populations or measurement methods. Patents and regulatory exclusivity can protect revenue, but they are different forms of protection with different terms. Check which rights cover the product, what the company owns and when protection may end. A long development period can consume years of commercial protection before meaningful revenue begins.
Manufacturing Can Determine Whether Sales Arrive
A successful study does not establish that a company can manufacture the treatment consistently at commercial scale. This matters especially for complex biologics and therapies that require specialised handling or individual production for each patient. Capacity constraints can limit sales even when demand exists, while poor manufacturing yields can reduce margins. Establish whether the company produces the medicine itself or depends on contractors, and what spending is required before launch. An outside manufacturer can reduce the need to build a facility, but it introduces contractual and supply dependencies. The valuation should include the cost and timing of delivering usable treatment to patients, rather than assuming that an approval immediately converts demand into cash. Write down a cautious adoption forecast and the assumptions that would have to improve for sales to exceed it.
Step 5 Review Cash and Future Financing
Cash Runway Must Reach Beyond the Next Announcement
Use the latest financial statements and subsequent financing announcements to establish available funding. Cash runway estimates how long available resources can support planned expenditure. Begin with cash and accessible investments, then examine operating cash outflow and commitments. If a hypothetical company has £120 million available and spends £10 million a month, simple division suggests twelve months. That estimate becomes unreliable if a larger trial begins, debt falls due or part of the cash is restricted. Review several reporting periods and management’s spending plans instead of treating the most recent quarter as a permanent rate. Accounting losses and cash consumption also differ, so use the cash flow statement to understand how much funding the business is actually consuming.
Timing is often the deciding issue. Funding through a trial announcement may still leave the company short of money for the analysis, regulatory discussions and next study that follow. Positive results can increase the need for capital because they justify a more expensive development programme. Delays create pressure too: slow recruitment can push a result beyond the period covered by existing funds. Compare the expected cash runway with a plausible schedule that includes setbacks, rather than management’s earliest possible milestone date. A company that must raise money before an uncertain result has less negotiating flexibility than one able to fund its work well beyond that event.
Financing Changes the Return per Share
Issuing shares provides cash while reducing each existing share’s percentage ownership. Suppose a company has 100 million shares and issues another 25 million. An investor holding one million shares goes from owning 1% to 0.8% if they buy no additional stock. That does not by itself establish that the financing destroys value; the cash may pay for work that makes the business more valuable. The judgement depends on the issue price and the expected return from the spending. Follow value per share through the funding plan. A growing company valuation can coexist with a disappointing shareholder return when the share count grows rapidly.
Other funding routes shift the trade-off. Borrowing introduces interest and repayment obligations, while selling royalty rights sacrifices part of future revenue. A partnership may reduce development costs but transfer control or territorial rights to another business. Warrants and convertible securities can add potential shares, depending on their terms, and employee equity awards also affect ownership. Read the financing documents rather than relying on the announced amount raised. Check fees, restrictions and any claims on company assets. For a business without steady product revenue, a seemingly convenient financing can create a difficult repayment or refinancing problem if clinical progress takes longer than expected. At the end of this step, estimate when fresh capital may be needed and how it could change the return per share.
Step 6 Assess Management and Capital Allocation
Compare management’s earlier statements with later disclosures before accepting its latest forecasts. Management should be judged partly on how it handles setbacks and spending decisions. Compare earlier forecasts with subsequent results and examine whether explanations remain consistent. A team willing to stop an unpromising programme can protect cash; repeatedly extending it may postpone an uncomfortable decision while consuming funds. Check whether incentives reward durable progress or mainly reward fundraising and short-term milestones. Scientific expertise matters, but so does experience running trials and preparing a business to sell a medicine. None of these observations guarantees success. They help establish whether management is making decisions that fit the company’s resources and explaining those decisions in a way shareholders can assess.
Turn that comparison into a short account of decisions rather than a judgement based on presentation style. Note whether management met development milestones, explained missed targets promptly and adjusted spending when evidence weakened. A missed recruitment target can have a reasonable explanation; a pattern of unexplained delays deserves closer attention. Read compensation disclosures and related-party transactions alongside the operating record, then assess whether the board provides relevant oversight. Experience launching a medicine can be valuable, but check whether that experience fits the product now being developed. End this step by identifying the management decisions you are relying on and what future behaviour would reduce your confidence in the team.
Step 7 Value the Shares Under Different Outcomes
Use Assumptions That Can Be Challenged
Bring together the clinical, commercial and financing assumptions from the preceding steps. For a profitable commercial biotech, revenue and cash flow provide a starting point, with adjustments for competition and the cost of maintaining the pipeline. For a developer, valuation usually depends on estimates of future product economics and the chance of reaching them. A risk adjusted model makes those assumptions explicit by allowing for uncertain outcomes and the time before money arrives. The arithmetic is straightforward; the inputs are not. Explain why the assumed success probability fits the evidence and why the commercial forecast fits the likely label. An average success rate for a broad industry category is not a reliable substitute for analysing the company’s programme.
Consider a deliberately simplified valuation. If a programme would be worth £1 billion today assuming commercial success, applying an assumed 20% chance gives £200 million before further adjustments. At 10%, it becomes £100 million; at 30%, £300 million. These are illustrative assumptions, not estimated probabilities for any actual treatment. A fuller model needs to account for future spending, timing and outcomes short of complete success. It also needs consistent treatment of costs: some spending will occur even if the programme later fails. The point of the exercise is to show which assumptions drive the result, so that a new trial finding can change the valuation for an identifiable reason.
Account for Cash, Obligations and Market Expectations
Share price alone says little about whether a biotech is cheap. Multiply it by the relevant share count, consider cash and debt, and inspect obligations that would consume cash even if development stopped. A company trading below its last reported cash balance may face substantial trial closure costs or continuing expenses, and that reported balance may already be out of date. Model financing in a consistent way, avoiding double counting cash inflows or dilution. Then compare optimistic and adverse scenarios with the current market value. A range grounded in clear assumptions is more useful than a precise target whose outcome depends on every part of the development plan working.
Market expectations explain why apparently good news can produce a falling share price. Investors may already have expected a stronger result, a broader approval or faster sales. An announcement can improve the scientific case while reducing the commercial forecast or revealing a larger funding need. Before a major event, write down what outcome the current valuation seems to require and how your estimate differs. Consider what would happen under an ambiguous result as well as a clear success or failure. Ambiguity can be costly because it may demand another trial, extend spending and leave the company raising money without having resolved the question investors thought the original study would answer. Keep an adverse, central and favourable case, with the assumptions and potential dilution visible in each.
Step 8 Choose Exposure and Set Position Size
Individual Companies and Funds Carry Different Risks
Decide whether you want to own the company directly or obtain broader sector exposure through a fund. Buying individual biotech shares gives control over which programmes and businesses you own, but that control comes with the work of assessing each one. A sector fund spreads exposure and reduces dependence on a single clinical result. Its composition still matters. A fund dominated by established producers will behave differently from one holding many small developers, and an equal-weight approach can produce different exposures from a market-value-weighted portfolio. Read the holdings and methodology, including how often the fund rebalances. Compare ongoing charges and trading spreads as well. Several funds can own the same companies, so holding more than one does not automatically provide much additional diversification.
The size of a biotech allocation deserves its own decision, separate from whether an individual company looks attractive at the current price. The allocation itself should reflect how losses would affect the rest of your finances. A collection of small positions can still depend on similar technology or on continued access to new capital. Consider those shared risks before counting holdings as separate bets. Money needed soon has little flexibility to wait through a clinical setback or a prolonged financing downturn. Decide how much exposure you can retain through a plausible adverse outcome before a rising share price makes the position feel safer than it is.
Allow for Losses Around Major Announcements
Trial results and regulatory decisions can move a share price before an investor has an opportunity to trade. A stop order cannot guarantee an exit at its trigger price if the market gaps, and smaller companies may have thin liquidity even in ordinary conditions. Size a position with that possibility in mind. A hypothetical holding representing 5% of a portfolio would reduce the portfolio by 4% if it lost 80% of its value, ignoring other movements. Whether that is tolerable depends on the investor’s circumstances and other exposures. The calculation is more useful before buying than after the event, when the loss has already restricted the choices available. Record the proposed holding as a percentage of the portfolio and calculate the effect of a severe loss before placing an order.
Step 9 Choose a Broker and Plan the Purchase
Confirm that the account can hold the intended security on acceptable terms. Broker selection affects the practical cost of holding overseas biotech shares. Compare exchange access and currency conversion charges, then check custody arrangements and the handling of corporate actions. Research services can help organise information, but they do not replace reading the company’s disclosures. Broker Listings provides a starting point for comparing providers; confirm the current account terms with the broker and establish which regulated entity would hold the account. When placing an order, examine the bid-ask spread and available liquidity. A limit order sets a price boundary if it executes, but it may remain unfilled, particularly during volatile trading after an announcement.
Before submitting the order, match the company name and ticker to the exchange, currency and security you intend to own. A similarly named instrument may provide different exposure, and a derivative is not the same holding as an ordinary share. Review the total cost of the proposed purchase, including any currency conversion, and decide the maximum price consistent with your valuation. If a trial announcement is imminent, make an explicit decision about whether to take that event risk before buying. Check the broker’s order confirmation afterwards and reconcile the quantity, price and charges with your instruction. The output of this step is a correctly identified holding purchased within the limits you set.
Step 10 Keep a Research Record and Review the Holding
Use the notes from the earlier steps to maintain a dated record of the assumptions behind the holding, with the next clinical event and financing need recorded separately. When new information arrives, identify which assumption changes and revise the associated estimate. If a trial is delayed, assess the effect on cash and competing programmes rather than treating the delay as automatically harmless or fatal. If results contradict the investment case, explain why continued ownership would still make sense before adding money. The original purchase price is an accounting fact; it does not determine the treatment’s prospects. A written record makes it harder to replace a failed thesis with a different one simply because selling would acknowledge a loss.
Set review points around financial reports and material clinical or regulatory disclosures, while remaining alert to unexpected announcements. At each review, update the cash estimate and identify any change to the expected development schedule before recalculating the valuation. Keep the previous assumptions so you can see whether the case improved or whether you simply became more optimistic. Write down the circumstances in which you would reduce or sell the holding, including evidence that contradicts the treatment thesis or financing terms that materially weaken the expected return. A review can also support doing nothing. The decision should follow the updated evidence and portfolio exposure, with the reason recorded while it is still clear.
